Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24450592 | 0.98 | MEN1 (0.44) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL3705231 | 0.98 | MEN1 (0.44) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL3715148 | 0.98 | MEN1 (0.44) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL3704510 | 0.97 | MEN1 (0.42) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL14151006 | 0.94 | KMT2A (0.47) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL11823754 | 0.94 | KMT2A (0.47) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL2743605 | 0.94 | KMT2A (0.47) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL23015039 | 0.94 | KMT2A (0.47) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL9000238 | 0.94 | KMT2A (0.47) | MEN1KMT2AKDM4CL3MBTL1NPC1 | |
| SCHEMBL6819838 | 0.94 | KMT2A (0.47) | MEN1KMT2AKDM4CL3MBTL1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117098541-A | Lipid nanoparticles for delivery of nucleic acids and related methods of use | 阿卡格拉医药公司 | 2023-11-21 | — | — | CN | disclosed |
| EP-4251170-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS, AND RELATED METHODS OF USE | Akagera Medicines, Inc. (US) | 2023-10-04 | — | — | EP | disclosed |
| US-20230126953-A1 | IONIZABLE CATIONIC LIPIDS | AKAGERA MEDICINES, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20230126953-A1 | IONIZABLE CATIONIC LIPIDS | AKAGERA MEDICINES, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-20220411394-A1 | Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof | AKAGERA MEDICINES, INC. (US) | 2022-12-29 | — | — | US | disclosed |
| WO-2022115645-A9 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS, AND RELATED METHODS OF USE | AKAGERA MEDICINES, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022115645-A9 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS, AND RELATED METHODS OF USE | AKAGERA MEDICINES, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022115645-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS, AND RELATED METHODS OF USE | AKAGERA MEDICINES, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| WO-2022115645-A1 | LIPID NANOPARTICLES FOR DELIVERY OF NUCLEIC ACIDS, AND RELATED METHODS OF USE | AKAGERA MEDICINES, INC. (US) | 2022-06-02 | — | — | WO | disclosed |
| US-20220162521-A1 | IONIZABLE CATIONIC LIPIDS | AKAGERA MEDICINES, INC. | 2022-05-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220411394-A1 | Lipid Nanoparticles for Delivery of Nucleic Acids and Methods of Use Thereof | ASGR1, LDLR, CD2BP2 | MEN1 4405/4885KMT2A 2048/4885KDM4C 3596/4885 |
| US-20220162521-A1 | IONIZABLE CATIONIC LIPIDS | PHOSPHO1, LIPA, ABHD16A | MEN1 3359/4885KMT2A 2465/4885KDM4C 3662/4885 |
| US-20230126953-A1 | IONIZABLE CATIONIC LIPIDS | PHOSPHO1, LIPA, ABHD16A | MEN1 3359/4885KMT2A 2465/4885KDM4C 3662/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.